- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Lp(a) Levels: A Continuous Relationship With ASCVD Levels and Consistent Throughout a Lifetime
Experts discuss the evidence supporting the continuous relationship between lipoprotein(a) (Lp[a]) levels and atherosclerotic cardiovascular disease (ASCVD), as recognized by the National Lipid Association, and explore how Lp(a) levels may change throughout a person’s lifetime or in response to lifestyle factors.
EP: 1.Lp(a) in ASCVD and Guideline Recommendations
EP: 2.Introduction and Burden of Atherosclerotic Disease and Aortic Stenosis
EP: 3.The Role of Prevention in the Management of Atherosclerotic Disease and Aortic Stenosis
EP: 4.Studying the Association Between Elevated Lp(a) Levels and Risk of Atherosclerotic Disease
EP: 5.Lp(a) Levels: A Continuous Relationship With ASCVD Levels and Consistent Throughout a Lifetime
EP: 6.How the Genetic Nature of Lp(a) Levels Influences Screening
EP: 7.A Case Study of Elevated Lp(a) Levels and Increased ASCVD Risk
EP: 8.The Role of Management Guidelines in Formulary Decision-Making and Recent Lp(a) Recommendations
EP: 9.Evidence Supporting 2024 Guidance for Lp(a) Testing
EP: 10.Factoring Cost, Recommendations, and Evidence Into Formulary Decisions about Lp(a) Testing
EP: 11.Assessing the Quality of Recommendations and Making Clinical Decisions About Lp(a) Testing
EP: 12.FDA-Approved and Pipeline Treatments for Elevated Lp(a) Levels
EP: 13.The Benefits of Lp(a) Testing in the Absence of Lp(a)-Lowering Therapies
EP: 14.Results of Lp(a) Testing to Modify Risk Assessment and Optimize Treatment
EP: 15.Lp(a) Testing: Prevalence and Strategies to Improve Uptake
EP: 16.Implementing Lp(a) Testing in Health Systems: Lessons From Real-World Experience
EP: 17.Implementing Lp(a) Testing: Learning From LDL Testing and Considering Value-Based Care Models
EP: 18.Present and Looking to the Future: Lp(a) Testing and Atherosclerotic Disease Management
Video content above is prompted by the following:
- Historically, Lp(a) levels of at least 125 nmol/L (or 50 mg/dL) have been considered elevated. However, the National Lipid Association—or NLA—now recognizes the relationship between Lp(a) and ASCVD to be continuous. Could you speak to the evidence supporting this conclusion?
- How, if at all, do Lp(a) levels change throughout a person’s lifetime or in response to lifestyle factors?
What It Takes to Improve Guideline-Based Heart Failure Care With Ty J. Gluckman, MD
August 5th 2025Explore innovative strategies to enhance heart failure treatment through guideline-directed medical therapy, remote monitoring, and artificial intelligence–driven solutions for better patient outcomes.
Listen
From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care
May 30th 2024In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.
Listen
